跳至主要内容
临床试验/IRCT20210415050976N14
IRCT20210415050976N14已完成1 期

Investigating the role of Elanzapine in reducing nausea and vomiting caused by chemotherapy in patients undergoing chemotherapy

Jahrom University of Medical Sciences0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients over 18 years of age with pathologically or cytologically confirmed malignancy
  • Patients undergoing emtogenic chemotherapy including carboplatin, irinotecan, cyclophosphamide
  • Serum creatinine =2.0 mg/dl.
  • Written informed consent

排除标准

  • being pregnant
  • Suffering from cognitive diseases and neurological diseases
  • Treatment with another psychiatric medication such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days before or during protocol treatment
  • Simultaneous abdominal radiotherapy
  • Simultaneous use of quinolone antibiotic treatment
  • Chronic alcoholism
  • Hypersensitivity to olanzapine
  • Known heart disease

研究者

发起方
Jahrom University of Medical Sciences

相似试验